
Opinion|Videos|January 16, 2025
Advancements, Unmet Needs, and Future Trends in the Treatment of NMIBC
Author(s)Mark D. Tyson, II, M.D., M.P.H.
A panelist discusses how significant unmet needs in NMIBC treatment persist around BCG supply shortages, optimal treatment sequencing, biomarker development for patient selection, and reducing treatment toxicity, while expressing optimism about emerging trends in combination therapies, novel delivery systems, and personalized medicine approaches based on molecular profiling.
Advertisement
- What are some unmet needs in the treatment landscape of NMIBC that investigational and approved agents still haven’t addressed?
- What advancements and future trends are you looking forward to in the field, considering the various MOAs of investigational agents?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: December 2025
2
How sex influences the bladder cancer tumor microenvironment
3
John Michael DiBianco, MD, highlights trial of stent omission after ureteroscopy
4
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
5



















